Literature DB >> 31426128

Impact of chronic obstructive pulmonary disease on mortality: A large national cohort study.

Hye Yun Park1, Danbee Kang2,3, Hyun Lee4, Sun Hye Shin1, Minwoong Kang2, Sunga Kong3, Chin Kook Rhee5, Juhee Cho2,3,6, Kwang Ha Yoo7.   

Abstract

BACKGROUND AND
OBJECTIVE: The global burden of chronic obstructive pulmonary disease (COPD) is increasing and COPD patients are at higher risk for all-cause mortality. We aimed to evaluate the impact of COPD on specific-cause mortality using national data.
METHODS: This was nationwide retrospective cohort study of 340, 767 adults aged 40-84 years who lacked COPD diagnosis at baseline between 1 January 2003 and 31 December 2013. Incident COPD was defined by reference to COPD claim codes and prescription of COPD medication at least twice annually. Cox proportional hazard ratio (HR) for each cause of death in the COPD group was compared to that of the non-COPD group, with other causes of death accounted as the competing risk.
RESULTS: All-cause mortality was higher in the COPD (2,978 per 100, 000 person-years) than the non-COPD group (629 per 100, 000 person-years) and adjusted HR was 1.41 (95% CI = 1.32, 1.50). The association was particularly strong for chronic lower airway disease (adjusted sub-HR = 9.67; 95% CI = 7.21, 12.96) and lung cancer (adjusted sub-HR = 3.16; 95% CI = 2.68, 3.71), and the association was stronger in those aged <60 years.
CONCLUSION: In this large national cohort, COPD patients were at a statistically significant higher risk for all-cause mortality than those without COPD. They were more likely to die from chronic lower airway disease, lung cancer and pneumonia than subjects without COPD. The impact of COPD on specific mortalities was stronger in younger subjects.
© 2019 Asian Pacific Society of Respirology.

Entities:  

Keywords:  chronic lower airway disease; chronic obstructive pulmonary disease; lung cancer; mortality

Mesh:

Year:  2019        PMID: 31426128     DOI: 10.1111/resp.13678

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  7 in total

Review 1.  Long-Term Outcome of Chronic Obstructive Pulmonary Disease: A Review.

Authors:  Yong Suk Jo
Journal:  Tuberc Respir Dis (Seoul)       Date:  2022-07-13

2.  Nationwide quality assessment of treatment for chronic obstructive pulmonary disease.

Authors:  Kyu Yean Kim; Kwang Ha Yoo; Hye Sook Choi; Bo Yeon Kim; Sang In Ahn; Yon U Jo; Chin Kook Rhee
Journal:  J Thorac Dis       Date:  2020-12       Impact factor: 2.895

3.  Association between Exposure to Ambient Air Pollution and Age-Related Cataract: A Nationwide Population-Based Retrospective Cohort Study.

Authors:  Jinyoung Shin; Hyungwoo Lee; Hyeongsu Kim
Journal:  Int J Environ Res Public Health       Date:  2020-12-10       Impact factor: 3.390

4.  Increased mortality in patients with non cystic fibrosis bronchiectasis with respiratory comorbidities.

Authors:  Hayoung Choi; Bumhee Yang; Jang Won Sohn; Hyun Lee; Yun Jin Kim; Sooim Sin; Yong Suk Jo; Youlim Kim; Hye Yun Park; Seung Won Ra; Yeon-Mok Oh; Sung Jun Chung; Yoomi Yeo; Dong Won Park; Tai Sun Park; Ji-Yong Moon; Sang-Heon Kim; Tae-Hyung Kim; Ho Joo Yoon
Journal:  Sci Rep       Date:  2021-03-29       Impact factor: 4.379

5.  Increased hospitalizations and economic burden in COPD with bronchiectasis: a nationwide representative study.

Authors:  Chin Kook Rhee; Seung Won Ra; Youlim Kim; Kyungjoo Kim
Journal:  Sci Rep       Date:  2022-03-09       Impact factor: 4.379

6.  Chronic obstructive pulmonary disease and lung cancer incidence in never smokers: a cohort study.

Authors:  Hye Yun Park; Danbee Kang; Juhee Cho; O Jung Kwon; Sun Hye Shin; Kwang-Ha Yoo; Chin Kook Rhee; Gee Young Suh; Hojoong Kim; Young Mog Shim; Eliseo Guallar
Journal:  Thorax       Date:  2020-04-02       Impact factor: 9.139

7.  Non-cytotoxic doses of shikonin inhibit lipopolysaccharide-induced TNF-α expression via activation of the AMP-activated protein kinase signaling pathway.

Authors:  Fang Zhang; Tao Pan; Xiaohui Wu; Xingchun Gao; Zhikui Li; Xinling Ren
Journal:  Exp Ther Med       Date:  2020-09-03       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.